Skip to Content
Merck
CN
  • A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease.

A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease.

PloS one (2015-05-15)
Thomas Chi, Man Su Kim, Sven Lang, Neelanjan Bose, Arnold Kahn, Lawrence Flechner, Sarah D Blaschko, Tiffany Zee, Gulinuer Muteliefu, Nichole Bond, Marysia Kolipinski, Sirine C Fakra, Neil Mandel, Joe Miller, Arvind Ramanathan, David W Killilea, Katja Brückner, Pankaj Kapahi, Marshall L Stoller
ABSTRACT

Ectopic calcification is a driving force for a variety of diseases, including kidney stones and atherosclerosis, but initiating factors remain largely unknown. Given its importance in seemingly divergent disease processes, identifying fundamental principal actors for ectopic calcification may have broad translational significance. Here we establish a Drosophila melanogaster model for ectopic calcification by inhibiting xanthine dehydrogenase whose deficiency leads to kidney stones in humans and dogs. Micro X-ray absorption near edge spectroscopy (μXANES) synchrotron analyses revealed high enrichment of zinc in the Drosophila equivalent of kidney stones, which was also observed in human kidney stones and Randall's plaques (early calcifications seen in human kidneys thought to be the precursor for renal stones). To further test the role of zinc in driving mineralization, we inhibited zinc transporter genes in the ZnT family and observed suppression of Drosophila stone formation. Taken together, genetic, dietary, and pharmacologic interventions to lower zinc confirm a critical role for zinc in driving the process of heterogeneous nucleation that eventually leads to stone formation. Our findings open a novel perspective on the etiology of urinary stones and related diseases, which may lead to the identification of new preventive and therapeutic approaches.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nitric-14N acid solution, ~10 N in H2O, 99.99 atom % 14N
Sigma-Aldrich
Os EnCat® 40, extent of labeling: 0.3 mmol/g Os loading
Sigma-Aldrich
Hydroxyapatite, puriss., meets analytical specification of Ph. Eur., BP, FCC, E341, ≥90% (calculated on glowed substance)
Sigma-Aldrich
Calcium phosphate tribasic, BioReagent, suitable for plant cell culture, powder
Sigma-Aldrich
Calcium phosphate tribasic, 34.0-40.0% Ca basis
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
Sigma-Aldrich
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)
Sigma-Aldrich
Hydroxyapatite, synthetic, 99.8% trace metals basis (excludes Mg)
Sigma-Aldrich
Hydroxyapatite, purum p.a., ≥90% (as Ca3(PO4)2, KT)
Sigma-Aldrich
Hydroxyapatite, powder, synthetic
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
Sigma-Aldrich
Xanthine, BioUltra, ≥99%
Sigma-Aldrich
Xanthine, ≥99.5% (HPLC), purified by recrystallization
Sigma-Aldrich
Nitric acid, 70%, purified by redistillation, ≥99.999% trace metals basis
Sigma-Aldrich
Nitric acid, ACS reagent, ≥90.0%
Sigma-Aldrich
Xanthine, ≥99%